Slide 1: Q2 2026 Results
Q2 2026 RESULTS Telephone Conference 17 July 2026 Theresa Agnew, CEO Alexander Kotsinas, CFO
Slide 2: Financial Highlights Q2 2026
Executive summary Sales breakdown Financials Concluding remarks Executive summary Sales breakdown Financials Concluding remarks Financial highlights Q2 2026 GROWTH EXCLUDING EBIT ADJUSTED EBIT CURRENCY EFFECTS MARGIN MARGIN 12% 30% 33% 2
Slide 3: Executive Summary Q2 2026
Executive summary Sales breakdown Financials Concluding remarks Executive summary Sales breakdown Financials Concluding remarks Executive Summary Q2 2026 • Net sales reached 440.9 MSEK (404.7), with growth excluding currency effects of 12% (9% including currency effects) • Sales in EMEA increased by
Slide 4: BioGaia Strategy
Executive summary Sales breakdown Financials Concluding remarks Executive summary Sales breakdown Financials Concluding remarks BioGaia Strategy Expansion through Grow Direct Markets the Core Gut Health / Colic Oral Health Immune Health Breakthrough Innovation Foundations People & Culture Invest for
Slide 5: Delivering on Our Strategy
Executive summary Sales breakdown Financials Concluding remarks Executive summary Sales breakdown Financials Concluding remarks Delivering on Our Strategy • Driving growth of Pediatric and Adult segments • Investing in marketing and sales activities to drive strong growth in direct markets Grow the
Slide 6: Launches
Executive summary Sales breakdown Financials Concluding remarks Executive summary Sales breakdown Financials Concluding remarks Launches Distributor Country Product BioGaia UK, Ireland BioGaia Protectis Plus with vitamin D easydropper 10 ml Abbott Chile BioGaia Pharax drops Unilab Lifescience Taiwan
Slide 7: Key Events
Executive summary Sales breakdown Financials Concluding remarks Executive summary Sales breakdown Financials Concluding remarks Key Events • April 28: Researchers at BioGaia have published new scientific findings in the journal Food and Bioprocess Technology, demonstrating that BioGaia’s patented Lo
Slide 8: Growth Excluding FX by Business Segment Q2
Executive summary Sales breakdown Financials Concluding remarks Executive summary Sales breakdown Financials Concluding remarks Growth Excluding FX by Business Segment Q2 Total Pediatrics Adults +12% +9% +23% 75% share of revenue 24% share of revenue Sales of BioGaia Protectis drops increased in Ame
Slide 9: Sales per Segment
Executive summary Sales breakdown Financials Concluding remarks Executive summary Sales breakdown Financials Concluding remarks Sales per Segment Sales per Segment Q2 2026 MSEK Q2 Q2 Change Total YTD YTD Change Total 1% 2026 2025 excl FX change 2026 2025 excl FX change 24% Pediatrics 332 310 9% 7% 6
Slide 10: Sales per Region
Executive summary Sales breakdown Financials Concluding remarks Executive summary Sales breakdown Financials Concluding remarks Sales per Region Sales per Region Q2 2026 MSEK Q2 Q2 Change Total YTD YTD Change Total 2026 2025 excl FX change 2026 2025 excl FX change 40% 37% EMEA 164 137 21% 20% 307 26
Slide 11: Financials
Alexander Kotsinas, CFO Financials 11
Slide 12: Key Financials
Executive summary Sales breakdown Financials Concluding remarks Executive summary Sales breakdown Financials Concluding remarks Key Financials Sales (MSEK) Gross profit (MSEK) EBIT (MSEK) +9% +9% 441 321 405 294 +22% 132 108 73% 73% 27% 30% Q2 2025 Q2 2026 Q2 2025 Q2 2026 Q2 2025 Q2 2026 12
Slide 13: Sales Bridge
Executive summary Sales breakdown Financials Concluding remarks Executive summary Sales breakdown Financials Concluding remarks Sales Bridge +9% 47 -11 405 441 Q2 2025 Growth excluding Currency Q2 2026 currency effects effect Change 12% -3% 13
Slide 14: Gross Margin per Segment
Executive summary Sales breakdown Financials Concluding remarks Executive summary Sales breakdown Financials Concluding remarks Gross Margin per Segment Gross margin Q2 2026 Q2 2025 YTD 2026 YTD 2025 Pediatrics 75% 74% 75% 75% Adult Health 65% 66% 64% 66% Total 73% 73% 72% 73% • Total: The lower gro
Slide 15: Operating Expenses (OPEX)
Executive summary Sales breakdown Financials Concluding remarks Executive summary Sales breakdown Financials Concluding remarks Operating Expenses (OPEX) MSEK Q2 2026 Q2 2025 Change YTD 2026 YTD 2025 Change Sales and Marketing -154 -138 11% -286 -251 14% Research and Development -28 -30 -7% -54 -53
Slide 16: Profit and Loss Statement
Executive summary Sales breakdown Financials Concluding remarks Executive summary Sales breakdown Financials Concluding remarks Profit and Loss Statement MSEK Q2 2026 Q2 2025 Change YTD 2026 YTD 2025 Change Sales 441 405 9% 813 771 6% Gross profit 321 294 9% 588 562 5% Percentage of revenue 73% 73%
Slide 17: Cashflow
Executive summary Sales breakdown Financials Concluding remarks Executive summary Sales breakdown Financials Concluding remarks Cashflow YTD YTD MSEK Q2 2026 Q2 2025 Change Change 2026 2025 Cash flow from operating activities 99 91 +8 165 172 -7 before changes in net working capital Changes in worki
Slide 18: Concluding Remarks
Executive summary Sales breakdown Financials Concluding remarks Executive summary Sales breakdown Financials Concluding remarks Concluding Remarks • The second quarter shows growth excluding currency effects of 12% • Both our pediatric segment (+9% growth excluding currency effects) and adult segmen
Slide 19: Q&A
Q&A
Slide 20: BioGaia.
BioGaia.